Scientists at the MIPT Institute for Future Biophysics have developed a new drug for the targeted treatment of lung cancer using KRAS inhibitors. As MIPT reports, the drug should pass in vitro tests before the end of 2024, after which preclinical and clinical studies will begin. The drug aims to destroy cancer cells while minimally affecting healthy tissue.
The head of the preclinical research laboratory, Anton Alasheev, noted that the development of such innovative drugs is an important part of the development of the Russian pharmaceutical industry. After the introduction of sanctions, Western companies suspended the registration of new drugs for Russia, emphasizing the importance of domestic developments. According to Alasheyev, the project began with the study of current trends in the global pharmaceutical industry, among which KRAS inhibitors are of particular interest. Two drugs based on them have already been registered: sotorasib and dagrasib.
The MIPT team has created a “library of compounds” and has now begun to synthesize them to test their activity. The institute has also launched a new technological site for the production of dosage forms. Alasheyev added that the state now supports local manufacturers, which makes drug development and production more profitable. A list of drugs developed by Physics and Technology researchers has been compiled for 2023, confirming the growing interest and demand for local chemical syntheses.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
